Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL56355 | 0.98 | DNM1 (0.52) | DNM1CA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL4913273 | 0.85 | DNM1 (0.56) | DNM1CYP2C9CYP2C19ALDH1A1HTT | |
| SCHEMBL3550114 | 0.83 | DNM1 (0.59) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL7345247 | 0.82 | DNM1 (0.53) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL23562968 | 0.81 | CA2 (0.39) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL13584322 | 0.81 | DNM1 (0.57) | DNM1CA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL55352 | 0.81 | DNM1 (0.58) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL3633164 | 0.80 | DNM1 (0.52) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL28034533 | 0.79 | DNM1 (0.66) | DNM1CA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL20509033 | 0.79 | CYP3A4 (0.39) | DNM1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-03-04 | — | — | US | disclosed |
| WO-2019144864-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-08-01 | — | — | WO | disclosed |
| CN-101883774-A | Thienopyrimidine and pyrazolopyrimidine compounds and their use as MTOR kinase and PI3 kinase inhibitors | WYETH CORP | 2010-11-10 | — | — | CN | disclosed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | DNM1 2343/4885CA1 3420/4885CA2 977/4885 |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | DNM1 2343/4885CA1 3420/4885CA2 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.